Bladder cancer and schistosomiasis

Journal of the Egyptian National Cancer Institute

Volumn 24, Issue 4, 2012, Pages 151-159

  Zaghloul, Mohamed S ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Bilharziasis; Biology; Bladder cancer; Chemotherapy; Cytogenetics; Pathology; Radical cystectomy; Radiotherapy; Schistosomiasis

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; METHOTREXATE; MITOMYCIN C; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CELL LINEAGE; CELL PROLIFERATION; CHEMORADIOTHERAPY; CHROMOSOME ABERRATION; CLINICAL FEATURE; CYSTECTOMY; CYSTOSCOPY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; EPIGENETICS; GENE MUTATION; GENOMICS; HETEROZYGOSITY LOSS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; META ANALYSIS (TOPIC); NON MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; POSTOPERATIVE COMPLICATION; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHISTOSOMA; SCHISTOSOMIASIS HAEMATOBIA; SURVIVAL RATE; URINARY TRACT CANCER; UROTHELIUM;

CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; HUMANS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SCHISTOSOMIASIS HAEMATOBIA; URINARY BLADDER NEOPLASMS;

EID: 84869774895     PISSN: 11100362     EISSN: 16879996     Source Type: Journal    
DOI: 10.1016/j.jnci.2012.08.002     Document Type: Review

References (101)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Siegel R., Ward E., Brawkey O., Jamal A. Cancer statistics 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer death. CA Cancer J Clin 2011, 61:212-236.
3. Zarzour A.H., Selim M., Abd-Elsayed A.A., Hameed D.A., Abdelaziz M.A. Muscle invasive bladder cancer in upper Egypt: the shift in risk factors and tumor characteristics. BMC cancer 2008, 8:250.
4. Lopez-Beltran A., Cheng L. Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. Hum Pathol 2006, 37:1371-1388.
5. Muscheck M., Abol-Enein H., Chew K., et al. Comparison of genetic changes in schistosome-related transitional and squamous bladder cancers using comparative genomic hybridization. Carcinogenesis 2000, 21:1721-1726.
6. Kallioniemi A., Kallioniemi O.P., Sudar D., et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992, 258:818-821.
7. Cheng L., Zhang D. Molecular genetic pathology 2008, Humana Press/Springer, NY, USA.
8. Kuper H., Adami H.O., Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med 2000, 248:171-183.
9. Gryseels B. Schistosomiasis. Infect Dis Clin North Am 2012, 2:383-397.
10. Fried B., Reddy A., Mayer D. Helminths in human carcinogenesis. Cancer Lett 2011, 305(2):239-249.
11. Ross A.G.P., Bartly P.B., Sleigh A.C., et al. Schistosomiasis. N Engl J Med 2002, 346(16):1212-1220.
12. Ferguson A.R. Associated bilharziasis and primary malignant disease of the urinary bladder with observations on a series of forty cases. J Pathol Bacteriol 1911, 16:76-94.
13. Ministry of Health and Population, Department of Endemic Diseases, Prevalence of schistosomiasis in Egypt over time, Egypt, 2004.
14. Gouda I., Mokhtar N., Bilal D., El-Bolkainy T., El-Bolkainy N.M. Bilharziasis and bladder cancer: a time trend analysis of 9843 patients. J Egypt Natl Canc Inst 2007, 19(2):158-162.
15. Rosin M.P., Saad el Din Zaki S., Ward A.J., Anwar W.A. Involvement of inflammatory reactions and elevated cell proliferation in the development of bladder cancer in schistosomiasis patients. Mutat Res 1994, 305:83-92.
16. Marletta M.A. Mammalian synthesis of nitrite, nitrate, nitric oxide, and nitrosating agents. Chem Res Toxicol 1988, 1:249-257.
17. Shokeir A.A. Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment. BJU Int 2004, 93:216-220.
18. Monograph on the evaluation of carcinogenic risks to humans: schistosomes, liver flukes and Helicobacter pylori. WHO: International Agency for Research on Cancer 1994, 61:9-175. IARC.
19. Smith J.H., Christie J.D. The pathobiology of Schistosoma haematobium infection in humans. Hum Pathol 1986, 17:333-345.
20. El-Bolkainy M.N., Mokhtar N.M., Ghonim M.A., Hussein M.H. The impact of schistosomiasis on the pathology of bladder carcinoma. Cancer 1981, 48:2643-2648.
21. Botelho M., Ferreia A.C., Olivieira M.J., Domingues A., Machado J.C., de Costa J.M. Schistosoma haematobium total antigen and decreased apoptosis of normal epithelial cells. Int J Parasitol 2009, 39:1083-1091.
22. Wu X.R. Urothelial tumorigenesis: a tale of divergent pathway. Nat Rev Cancer 2005, 5:713-725.
23. Botelho M.C., Machado J.C., de Costa J.M. Schistosoma hematobium and bladder cancer. Virulence 2010, 1(2):84-87.
24. Jacobs B.L., Lee C.T., Montie J.E. Bladder cancer in 2010: how far have we come?. CA Cancer J Clin 2010, 60(4):244-272.
25. Mc Conkey D.J., Lee S., Choi W., et al. Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression. Urol Oncol 2010, 28(4):429-440.
26. Abdel Wahab A.H., Abo-Zeid H.I., El-Husseini M.I., Ismail M., El-Khor A.M. Role of loss of heterozygosity on chromosomes 8 and 9 in the development and progression of cancer bladder. J Egypt Natl Canc Inst 2005, 17(4):260-269.
27. Chaudhary K.S., Lu K.S., Abel P.D., et al. Expression of bcl-2 and p53 oncoproteins in schistosomiasis-associated transitional and squamous cell carcinoma of the urinary bladder. Br J Urol 1997, 79:78-84.
28. El-Sheikh S.S., Madaan S., Alhasso A., Abel P., Stamp G., Lalani E.N. Cyclooxygenase-2: a possible target in Schistosoma associated bladder cancer. Br J Urol 2001, 88:921-927.
29. Tsutsumi M., Tsai Y.C., Gonzalgo M.L., Nichols P.W., Jones P.A. Early acquisition of homozygous deletions of p16/p19 during squamous cell carcinogenesis and genetic mosaicism in bladder cancer. Oncogene 1998, 17:3021-3027.
30. Fadl-Elmula I., Kytola S., Leithy M.E., et al. Chromosomal aberrations in benign and malignant bilharzia-associated bladder lesions analyzed by comparative genomic hybridization. BMC Cancer 2002, 2:5.
31. Armengol G., Eissa S., Lozano J.J., et al. Genomic imbalances in Schistosoma-associated and non Schistosoma-associated bladder carcinoma: an array comparative genomic hybridization analysis. Cancer Genet Cytogenet 2007, 177:16-19.
32. Vauhkonen H., Bohling T., Eissa S., Shoman S., Knuutila S. Can bladder adenocarcinomas be distinguished from schistosomiasis associated bladder cancer by using comparative genomic hybridization analysis?. Cancer Genet Cytogen 2007, 177:153-157.
33. Heim S., Mitelman F. Cancer cytogenetics 1995, Wiley-Liss Inc., New York. 2nd edition.
34. Hogland M. The bladder cancer genome: chromosomal changes as prognostic markers, opportunities and obstacles. Urol Oncol 2012, 30:535-540.
35. Aly M.S., Khaled H.M., Emara M., Hussein T.D. Cytogenetic profile of locally advanced and metastatic Schistosoma-related bladder cancer and response to chemotherapy. CancerGenet 2012, 205(4):156-162.
36. Abraham R., Pagano F., Gonella L.G., et al. Chromosomal deletions in bladder cancer: shutting down pathways. Front Biosci 2007, 12:826-838.
37. Koraitim M.M., Metwalli N.E., Atta M.A. El-Sadr. Changing age incidence and pathological types of schistosoma-associated bladder carcinoma. J Urol 1995, 154:1714-1716.
38. Zaghloul M.S., Nouh A., Moneer M., El-Baradie M., Nazmy M., Younis A. Time-trend in epidemiological and pathological features of schistosoma-associated bladder cancer. J Egypt Natl Canc Inst 2008, 20(2):168-174.
39. Salem H.K., Mahfouz S. Changing patterns (age, incidence and pathological types) of schistosoma-associated bladder cancer in Egypt in the past decade. Urology 2012, 79(2):379-383.
40. Zaghloul M.S. Radiation as adjunctive therapy to cystectomy for bladder cancer.Is there a difference for bilharzial association?. Int. J. Radiat. Oncol. Biol. Phys. 1994, 28:783.
41. Zaghloul M.S. Distant metastasis from bilharzial bladder cancer. Cancer 1996, 77:743-749.
42. Miller L.S. Bladder cancer. Superiority of preoperative irradiation and cystectomy in clinical stages B2 and C. Cancer 1977, 39:973-980.
43. Werf-Messing B.V., Friedell G.H., Menon R.S., Raigopa S.M. Carcinoma of the urinary bladder T3 Nx MO treated by preoperative irradiation followed by simples cystectomy. IntJ Radiclt Oiicol Biol Phys 1982, 1847-1855.
44. Greven K.M., Spera J.A., Solin L.W. Local recurrence after cystectomy alone for bladder carcinoma. Cancer 1992, 69:2767-2770.
45. Visser O., Nieuwenhuijzen J.A., Horenblas S. Local recurrence after cystectomy and survival of patients with bladder cancer: a population based study in greater Amsterdam. J Urol 2005, 174:97-102.
46. Cheng L., Weaver A.L., Leibovich B.C., et al. Predicting the survival of bladder carcinoma patients treated with radical cystectomy. Cancer 2000, 88:2326-2332.
47. Volkmer B.G., Kuefer R., Bartsch G.C., et al. Oncological followup after radical cystectomy for bladder cancer - is there any benefit?. J. Urol. 2009, 181(4):1587-1593.
48. Gupta N.P., Kolla S.B., Seth A., et al. Radical cystectomy for bladder cancer: a single center experience. Indian J. Urol 2008, 24(1):54-59.
49. El-Said A., Omar S., Ibrahim A.S., et al. Bilharzial bladder cancer in Egypt. A review of 420 cases of radical cystectomy. Jap. J Clin Oncol 1979, 9:117-122.
50. Zaghloul M.S., Awwad H.K., Omar S., et al. Postoperative radiotherapy of carcinoma in bilharzial bladder. Improved disease-free survival through improving local control. Int. J. Radiat. Oncol. Biol. Phys. 1992, 22:511-517.
51. Zaghloul M.S. Adjuvant radiation therapy for locally advanced bladder cancer. Touchbriefings, US oncological disease issue 2006, 2:86-89.
52. Ghoneim M.A., El-Mekresh M.M., El-Baz M.A., El-Attar I.A., Ashamallah A. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J Urol 1997, 158:393-399.
53. Ghoneim M.A., Abdel-Latif M. El-Mekresh M et al.: Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 year later. J. Urol. 2008, 180(1):121-127.
54. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou J. Guidelines on TaT1 (non-muscle invasive) bladder cancer.European Association of Urology Web site. http://www.uroweb.org/professional resources/guidelines/online accessed August 5,2012.
55. Mariappan P., Zachou A., Grigor K.M. Detrusor muscle in the first, apparently complete transurethral resection of the bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence and is dependent on operator experience. Eur Urol 2010, 57(5):843-849.
56. Grimm M., Steinhoff Ch., Simon X., et al. Effect of routine repeat transurethral resection for superficial bladder cancer. A long-term observation study. J Urol 2003, 170:433-437.
57. Malmstrom P., Sylvester R.J., Crawford D.E., et al. An individual patient data metaanalysis of the long-term outcome of randomized studies comparing intravesical mitomycin C versus bacillus calmette-guerin for non-muscle=invasive bladder cancer. Eur Urol 2009, 56(2):247-256.
58. Zaghloul M.S., Gouda I. Bladder cancer and schistosomiasis: Is there a difference for the association. Bladder cancer- ftom basic science to robotic surgery 2012, 195-218. In Tech open publisher, Rajeko, Croatia. A.E. Canda (Ed.).
59. Ali-El-Dein B., Al-Marthoon M.S., Abdel Latif M., et al. Survival after primary and deferred cystectomy for stage T1q transitional cell carcinoma of the bladder. Urol Ann 2011, 3(3):127-132.
60. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
61. Zaghloul M.S. Adjuvant and neoadjuvant radiotherapy for bladder cancer: revisited. Future Oncol. 2010, 6(7):1177-1191.
62. Gschwend J.E., Dahm P., Fair W.R. Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy. Eur Urol. 2002, 41(4):440-448.
63. Takahashi A., Tsukamoto T. Et al.:Radical cystectomy for invasive bladdercancer, results of multi-institutional pooled analysis. Jpn. J. Clin. Oncol. 2004, 34:14-19.
64. Rogers C.G., Palapattu G.S., Shariat S.F., et al. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma for the bladder compared with transitional cell carcinoma of the bladder. J Urol 2006, 175:2048-2053.
65. Scosyrev E., Yao J., Messing E. Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment?. Urology 2009, 73:822-827.
66. Ploeg M., Aben K.K. Hulsbergen-van de Kaa CA et al.: Clinical epidemiology of nonurothelial bladder cancer: analysis of The Netherlands Cancer Registry. J. Urol. 2010, 183(3):915-920.
67. Awwad H.K., Baki H.A. El Bolkainy et al.: Preoperative irradiation of T3 carcinoma in Bilharzial bladder. Int. J. Radiat. Oncol. Biol. Phys. 1979, 5:787-794.
68. Ghoneim M.A., Ashamalla A.G., Awwad H.K., Whitmore W.F. Randomized trial of cystectomy with or without preoperative radiotherapy for carcinoma of the bilharzial bladder. J. Urol. 1985, 134:266-268.
69. Huncharek M., Muscat J., Geschwind J.F. Planned preoperative radiation therapy in muscle invasive bladder cancer. Results of metaanalysis. Anticancer Res. 1998, 18:1931-1934.
70. Reisinger S., Mohiuddin M., Mulholland S. Combined pre- and post-operative adjuvant radiation therapy for bladder cancer - a ten year experience. Int. J. Radiat. Oncol. Biol. Phys. 1992, 24:463-468.
71. Cozzarini C., Pelegrini D., Fallini M., et al. Reappraisal of the role of adjuvant radiotherapy in muscle-invasive transitional cell carcinoma of the bladder. Int. J. Radiat. Oncol. Biol. Phys. 1999, 45:221.
72. Zaghloul M.S., Mohran T.Z., Saber R.A., Agha N. Postoperative radiotherapy in bladder cancer. J. Egypt. Nat. Cancer Inst. 2002, 14:161-168.
73. Zaghloul M.S., Nouh A., Nazmy M., et al. Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients. Urol Oncol 2006, 24:13-20.
74. El-Moneim H.A., El-Baradie M.M., Younis A., Ragab Y., Labib A., El-Attar I. A prospective randomized trial for postoperative vs. preoperative adjuvant radiotherapy for muscle-invasive bladder cancer. Urol Oncol 2011, Epub ahead of print.
75. Stenzl A, Witjes A, Comperat E et al. Guirelines on bladder cancer muscle-invasive and metastatic. European Association of Urology 2012. www.uroweb.org/professional resourse/ guidelines accessed August 5,2012.
76. Zaghloul M.S. The need to revisit adjuvant and neoadjuvant radiotherapy in bladder cancer. Exp Rev Anicancer Ther 2010, 10(10):1527-1528.
77. Vaughn D.J., Malkowicz S.B. Neoadjuvant chemotherapy in patients with invasive bladder caner. Urol Clin North Am. 2005, 32:231-237.
78. Winquist E., Kichner T.S., Segal R., et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 2004, 171:561-569.
79. Vale C.L. Advanced Bladder Cancer Meta-analysis Collaboration. Adjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev 2006, CD006018.
80. Ruggeri E.M., Giannarelli D., Bria E., et al. Adjuvant chemotherapy in muscle-invasive bladder cancer: a pooled analysis from phase III studies. Cancer 2006, 106:783-788.
81. Khaled H., Zaghloul M., Ghoneim M., et al. Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive bladder cancer: Effect on bladder preservation and survival. Proc Am Soc Clin Oncol 2003, 22:411. abstr 1652.
82. Rödel C. Current status of radiation therapy and combined-modality treatment for bladder cancer. Strahlenther Onkol. 2004, 180(11):701-709.
83. Zaghloul M.S., Mousa A.G. Trimodality treatment for bladder cancer: does modern radiotherapy improve the end results?. Expert Rev Anticancer Ther. 2010, 10(12):1933-1944.
84. Kachnic L.A., Kaufman D.S., Heney N.M., et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol. 1997, 15(3):1022-1029.
85. Shipley W.U., Winter K.A., Kaufman D.S., et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 1998, 16(11):3576-3583.
86. Arias F., Domínguez M.A., Martínez E., et al. Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. Int J Radiat Oncol Biol Phys. 2000, 47(2):373-378.
87. Tester W., Porter A., Asbell S., et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int. J. Radiat. Oncol. Biol. Phys. 1993, 25(5):783-790.
88. Sauer R., Birkenhake S., Kühn R., Wittekind C., Schrott K.M., Martus P. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys. 1998, 40(1):121-127.
89. Sabaa M.A., El-Gamal O.M., Abo-Elenen M., Khanam A. Combined modality treatment with bladder preservation for muscle invasive bladder cancer. Urol. Oncol. 2010, 28:14-20.
90. Aboziada M., Hamza H.M., Abdelrahman A.M. Initial results of bladder preserving approach by chemoradiotherapy in patients with muscle invading transitional cell carcinoma. J Egypt Nat Cancer Inst 2009, 21(2):167-174.
91. Dhar N.B., Campbell S.C., Zippe C.D., et al. Outcomes in patients with urothelial carcinoma of the bladder with limited pelvic lymph node dissection. BJU Int. 2006, 98(6):1172-1175.
92. Manoharan M., Ayyathurai R., Soloway M.S. Radical cystectomy for urothelial carcinoma of the bladder: an analysis of perioperative and survival outcome. BJU Int. 2009, 104(9):1227-1232.
93. Abdollah F., Sun M., Jeldres C., et al. Survival after radical cystectomy of non-bilharzial squamous cell carcinoma vs urothelial carcinoma: a competing-risks analysis. BJU Int. 2012, 109(4):564-569.
94. Lughezzani G., Sun M., Shariat S.F., et al. A population-based competing-risk analysis of the survival of patients treated with radical cystectomy for bladder cancer. Cancer 2011, 117(1):103-109.
95. Nishiyama H., Habuchi T., Watanabe J., et al. Clinical outcome of a large-scale multiinstitutional retrospective study for locally advanced bladder cancer: a survey including 1131 patients treated during 1990-2000 in Japan. Eur Urol 2004, 45:176-181.
96. Niu H.T., Xu T., Zhang Y.B., et al. Outcomes for a large series of radical cystectomies for bladder cancer. Eur. J. Surg. Oncol. 2008, 34(8):911-915.
97. El-Mekresh M.M. El-Baz MA, Abol-Enein H, Ghoneim MA. Primary adenocarcinoma of the urinary bladder: a report of 185 cases. Br J Urol 1998, 82(2):206-212.
98. Khaled H., El-Hattab O., Moneim D.A., Kassem H.A., Morsi A., Sherif G. A prognostic index (bladder prognostic index) for bilharzial-related invasive bladder cancer. Urol. Oncol. 2005, 23:254-260.
99. Zaghloul M.S. El Baradie Nouh MA, Abdel-Fatah S, Taher A and Shalaan M. Prognostic index for primary adenocarcinoma of the urinary bladder. Gulf J. Oncol 2007, 1(2):47-54.
100. Madersbacher S., Hochreiter W., Burkhard F., et al. Radical cystectomy for bladder cancertoday: a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003, 21:690-696.
101. Ho C.H., Huang C.Y., Lin W.C., et al. Radical cystectomy in the treatment of bladder cancer: oncological outcome and survival predictors. J. Formos. Med. Assoc. 2009, 108(11):872-878.